SOURCE: CytoSorbents

October 22, 2013 08:30 ET

CytoSorbents to Report Third Quarter Fiscal 2013 Operating and Financial Results

MONMOUTH JUNCTION, NJ--(Marketwired - Oct 22, 2013) -  CytoSorbents Corporation (OTCQB: CTSO), a critical care focused company commercializing its European Union approved CytoSorb® blood filter to treat life-threatening illnesses in the intensive care unit, will report Q3 2013 earnings after the market close on Wednesday, November 6, 2013. 

CytoSorbents management will also host a live conference call and presentation webcast that will recount both operational and financial progress during the quarter. 

Conference Call Details:
Date: Wednesday, November 6, 2013
Time: 4:15 p.m. Eastern
Participant Dial-In: (480) 629-9665
Live Presentation Webcast:

It is recommended that participants dial in approximately 10 minutes prior to the start of the call. There will also be a simultaneous live webcast of the conference call that can be accessed through the following audio feed link:

An archived recording of the conference call will be available under the Investor Relations section of the Company's website at

Investors are encouraged to submit their questions in advance as soon as possible to Mr. Valter Pinto of Alliance Advisors at

About CytoSorbents Corporation

CytoSorbents is a critical care focused therapeutics company using blood purification to control severe inflammation -- with the goal of preventing or treating multiple organ failure caused by uncontrolled inflammation in life-threatening illnesses. Organ failure is the cause of nearly half of all deaths in the intensive care unit, with little to improve clinical outcome. CytoSorb®, the Company's flagship product, is approved in the European Union as a safe and effective extracorporeal cytokine filter, designed to reduce the "cytokine storm" that could otherwise cause massive inflammation, organ failure and death in common critical illnesses such as sepsis, burn injury, trauma, lung injury, and pancreatitis. These are conditions where the mortality is extremely high, yet no effective treatments exist. CytoSorbents' purification technologies are based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. CytoSorbents has numerous products under development based upon this unique blood purification technology, protected by 32 issued US patents and multiple applications pending, including HemoDefend™, ContrastSorb, DrugSorb, and others. Additional information is available for download on the Company's website:

Forward-Looking Statements
This press release includes forward-looking statements intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release are not promises or guarantees and are subject to risks and uncertainties that could cause our actual results to differ materially from those anticipated. These statements are based on management's current expectations and assumptions and are naturally subject to uncertainty and changes in circumstances. We caution you not to place undue reliance upon any such forward-looking statements. Actual results may differ materially from those expressed or implied by the statements herein. Risk factors are detailed in the Company's Form 10-K filed with the SEC on April 3, 2013, which is available at

Contact Information

  • Company Contact:
    CytoSorbents Corporation
    Dr. Phillip Chan
    Chief Executive Officer
    (732) 329-8885 ext. *823
    Email Contact

    Investor Contact:
    Alliance Advisors, LLC
    Alan Sheinwald
    (914) 669-0222
    Email Contact

    Valter Pinto
    (914) 669-0222 x201
    Email Contact

    Media Contact:
    JQA Partners
    Jules Abraham
    (917) 885-7378
    Email Contact